Literature DB >> 8058067

Multiple signaling pathways activate the chicken progesterone receptor.

Y Zhang1, W Bai, V E Allgood, N L Weigel.   

Abstract

We have previously reported that treatment of CV1 cells, transiently transfected with DNA encoding the chicken progesterone receptor (cPR) and a reporter plasmid PREtkCAT, with either 8-Br-cAMP or okadaic acid resulted in ligand-independent transcriptional activation of the cPR. The surprising finding that cPR can be activated in the absence of hormone has been followed by numerous studies from other laboratories examining the effects of modulators of kinases and phosphatases on the activity of other steroid receptors. These studies have yielded mixed results: ligand-independent activation has been observed in some cases, but not in others. In order to determine whether the ligand-independent activation of cPR was restricted to a specific reporter and cell type and to better characterize this phenomenon, the studies in this report were undertaken. Using both the original reporter, PREtkCAT, and a simpler reporter, GRE2E1bCAT, we found that ligand-independent activation of the cPR can be induced in both CV1 and HeLa cells. The magnitude of the response and the response of the reporter alone differed in the two cell types. Further analysis of the activation of cPR by inhibitors of protein phosphatases showed that inhibition of phosphatase 1 rather than phosphatase 2A was necessary for activation of cPR. Finally, treatment with vanadate, an inhibitor of phosphotyrosine phosphatases, or epidermal growth factor resulted in activation of cPR. These studies suggest that signals transduced through multiple signaling pathways can activate cPR.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8058067     DOI: 10.1210/mend.8.5.8058067

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  15 in total

1.  Modulation of AP-1 activity by the human progesterone receptor in endometrial adenocarcinoma cells.

Authors:  A M Bamberger; C M Bamberger; B Gellersen; H M Schulte
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

Review 2.  Steroid hormone receptors and their regulation by phosphorylation.

Authors:  N L Weigel
Journal:  Biochem J       Date:  1996-11-01       Impact factor: 3.857

Review 3.  Minireview: Tipping the balance: ligand-independent activation of steroid receptors.

Authors:  Marcela A Bennesch; Didier Picard
Journal:  Mol Endocrinol       Date:  2015-01-27

4.  Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity.

Authors:  Ramesh Narayanan; Dean P Edwards; Nancy L Weigel
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

5.  Redefining hormone resistance in prostate cancer.

Authors:  Christopher J Hoimes; W Kevin Kelly
Journal:  Ther Adv Med Oncol       Date:  2010-03-01       Impact factor: 8.168

6.  Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator.

Authors:  Ramesh Narayanan; Abayomi A Adigun; Dean P Edwards; Nancy L Weigel
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

Review 7.  Neuroendocrine peptides in the prostate.

Authors:  P J Gkonos; A Krongrad; B A Roos
Journal:  Urol Res       Date:  1995

8.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation.

Authors:  G Bunone; P A Briand; R J Miksicek; D Picard
Journal:  EMBO J       Date:  1996-05-01       Impact factor: 11.598

9.  Steroid-regulated growth of DDT1MF-2 cells is profoundly influenced by culture conditions.

Authors:  D J Lamb; M Ray
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-12       Impact factor: 2.416

10.  Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth.

Authors:  Cecilia J Proietti; Cinthia Rosemblit; Wendy Beguelin; Martín A Rivas; María Celeste Díaz Flaqué; Eduardo H Charreau; Roxana Schillaci; Patricia V Elizalde
Journal:  Mol Cell Biol       Date:  2008-12-22       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.